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BACKGROUND:Some cancer patients are immuno-compromised, and it has been long felt that immune-intervention is not compatible
with standard chemotherapies. However, increasing evidence suggests that standard chemotherapy drugs may stimulate beneficial
changes in both the immune system and tumour.
METHODS: We have assessed the expression of human leucocyte antigen class 1 (HLA1) on tumour cells before and after
chemotherapy agents (cyclophosphamide, oxaliplatin or gemcitabine). In addition, we show that chemotherapy-stressed tumour cells
may release cytokines that enhance the interactions between dendritic cells (DCs) and T cells into growth media.
RESULTS:Here we report that some chemotherapy agents can increase HLA1 expression in tumour cells, even when expression is low.
Increases were associated with killing by cytotoxic T cells, which were negated by HLA1-blockade. Furthermore, T-cell function, as
indicated by increased proliferation, was enhanced as supernatants derived from tumours treated with chemotherapy augmented
DC-maturation and function.
CONCLUSIONS: There is evidence that a facet of immune surveillance can be restored by appropriate chemotherapy agents. Also,
tumours exposed to some chemotherapy may secrete cytokines that can mature DCs, which ultimately enhances T-cell responses.
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Cancer is associated with chronic inflammation and marked
systemic immune suppression (O’Byrne and Dalgleish, 2001;
Dalgleish and O’Byrne, 2002, 2006; Evans et al, 2006). Indeed,
the evasion of immune surveillance and negation of its function
are hallmarks or cancer. These aspects are widely overlooked
(Hanahan and Weinberg, 2000), and the development of new
therapies in cancer have primarily focussed on tumour killing and
disturbing tumour-microenvironment interactions. These typical
therapeutic approaches have resulted in impressive activities, and
as our understanding of the pathogenetic pathways underlying
cancer improve, new drugs that correct specific molecular defects
in cancer will be formulated to fuel further successes (Workman
and Kaye, 2002). Drawbacks exist, however, that limits the long-
term efficacy of these drugs, such as the gradual loss of activity
(Liu, 2008). These failings stem from the direct effect of the drugs,
and develop gradually, as the cancer adapts to treatment and
develops drug resistance. One way to prevent these adverse events
is to ensure that tumour cells are cleared more efficiently and
residual tumour cells are minimised. For this reason, the
restoration of a competent immune system that is innately
programmed to remove foreign material is an attractive aim
(Bhardwaj, 2007; Liu et al, 2009).
Cytotoxic chemotherapeutic drugs affect rapidly growing cells,
and as a consequence cause collateral damage to cells of the
immune system. In this regard they are considered immuno-
suppressive. However, there is increasing evidence to suggest that
some cancer chemotherapies may actually aid immunotherapy
by activating the immune system rather than suppressing it
(Chaudhuri et al, 2009). This is supplementary to the conventional
cytotoxic effects, and may be a product of enhancements in the
adaptive response. For example, the nucleoside analogue gemci-
tabine (GEM), in addition to its apoptotic effects, selectively
promotes the cell-mediated immune response over the humoral
immune response by selectively inhibiting B-cell proliferation
(Nowak et al, 2002), decreasing memory T cells, and promoting the
activation of naive T cells (Plate et al, 2005) and function of CD8þ
T cells (Suzuki et al, 2005). Immunopotentiation is also achieved
in part by the inhibitory effect of GEM on myeloid-derived
suppressor cells (Bronte et al, 2000). Furthermore, maximising the
interactions between T cells and professional antigen presenting
cells (APCs), such as dendritic cells (DCs), have been shown
to enhance adaptive responses, which ultimately leads to the
elimination of tumour (Steinman and Banchereau, 2007). The
maturation of DCs has a key role in initiating T-cell responses as
they possess the ability to initiate primary adaptive immune
response through the capture, processing and presentation of
antigen to naive CD4þ and CD8þ T cells. These have pivotal
roles in the induction of T-cell-mediated anti-tumour responses
in vivo.
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sIn addition to the effects on immune cells, the process of
immunosurveillance can also be a target for chemotherapy; indeed,
the ability to evade immunity is a regular feature of cancer cells.
The molecular transformations that occur during oncogenesis,
which cause cancer cells to be pro-survival and anti-apoptotic are
the same ones that interfere with immune responses against
tumour cells (Fuchs and Matzinger, 1996; Pardoll, 2003). For
instance, dysregulation of the RAS and mitogen activated protein
kinase signalling pathways that promote anti-apoptotic and pro-
survival behaviour in some cancers (Dhillon et al, 2007; Roberts
and Der, 2007) can also interfere with human leucocyte antigen
class 1 (HLA1) antigen processing on tumour cells. As cytotoxic
T cells are restricted by HLA1 and kill tumour cells only in the
presence of HLA1, tumours lacking this antigen may become
undetectable to immune cells. It is predicted that restoration of
HLA1 expression could re-initialise immune visibility in tumour
cells.
As part of our ongoing studies to investigate the effect of
chemotherapy on immune function, we explored the effect of
supernatant derived from tumour cells exposed to chemotherapy,
on DC function, to test the hypothesis that chemotherapy-stressed
tumour cells secrete cytokines and other factors that promote the
antigen presenting behaviour of DCs. In addition, we explored the
role of chemotherapy on the HLA1 expression on tumour cells
to see if restoration of HLA1 expression on tumour cells may
re-engage immune-cell function and enhance tumour cell death.
MATERIALS AND METHODS
Reagents
Cyclophosphamide (CPM; Sigma, Dorset, UK), GEM (Eli Lilly
Pharmacy, St George’s Hospital, London, UK) and oxaliplatin
(OXP; Sigma) were dissolved in dimethyl sulphoxide (DMSO) to
create 10mM stock solutions that were maintained at  201C for no
longer than 4 weeks. For in vivo studies, the drugs were dissolved
in 0.5% DMSO in phosphate-buffered saline (PBS) and stored at
41C for the duration of the experiment. All controls used in our
studies involved treatment with equal amounts of DMSO, the final
concentrations of which were o0.1%.
Cell culture
The human cancer cell lines A549 (lung), Caki2 (kidney), HCT116
(colon), MCF7 (breast) and PC3 (prostate) were obtained from the
Cancer Research UK Cell Production Laboratories and maintained
in culture medium supplemented with 10% (v/v) foetal bovine
serum (FBS), 2mML -glutamine and 1  penicillin/streptomycin
(basal culture medium). All cell lines were incubated in a
humidified atmosphere with 5% CO2 in air at 371C, and discarded
when the passage number exceeded 15.
To study the effect of CPM, GEM and OXP on cell growth, cells
growing exponentially were added to 96-well plates at a density of
5 10
4 per well. Drugs were then added to the wells, ensuring an
equal volume of 200ml across the plate. Cell number was assessed
at 72h using the methylthiazoletetrazolium (MTT) assay, and the
concentration of each drug required to reduce cell viability by
50% (IC50) was determined using the sigmoid Emax model as
described previously (Liu et al, 2008).
HLA1
Exponentially growing cells were reset in fresh culture medium at
2 10
5 cellsml
 1. Following a settling-in period of 24h, cells were
treated for 3 days with equi-active concentrations of CPM (10mM),
GEM (1mM) or OXP (5mM). Exhausted culture medium (super-
natant) was gently aspirated and used in our DC studies. Cells were
harvested (1 10
5) and washed twice in wash buffer (PBS
containing 1% (v/v) FBS and 0.09% (v/v) NaN3), and then incu-
bated with a fluorescein isothiocyanate-conjugated anti-HLA1
antibody (anti-HLA–ABC – 1:1000: BD Biosciences, Oxford, UK)
for 30min at 41C. Acquisition of data was carried out within
1h using a FACSCalibur (BD Biosciences). In all, 10000 cells were
analysed for each sample, and then the mean fluorescence intensity
(MFI) of HLA1 was determined using the program WinMDI v2.9
(http://facs.scripps.edu/software.html).
Cytotoxicity assay
T cells were isolated from pathologically healthy donor buffy
coats (National Blood Service, London, UK) using positive cell
isolation with magnetic beads coated with anti-CD3 (Miltenyi
Biotec, Surrey, UK) according to manufacturer’s instructions. CD3
purities, as assessed by flow cytometry, that were greater than 90%
were used. Tumour cells pre-treated with CPM, GEM or OXP for
3 days were reset in culture medium at 1 10
4 cells per well in a
96-well plate in the presence or absence of a HLA1 blocking
antibody (1–10mgml
 1; Cambridge BioScience, Cambridge, UK).
Cells were allowed to adhere before adding T cells at an
effector:target ratio of 20:1. After a 24-h incubation period,
cell-free media were removed for the assessment of lactate
dehydrogenase (LDH) release using a proprietary assay kit
(Cambridge BioScience). Non-adherent T cells were removed by
washing twice in PBS and the tumour cell numbers were assessed
in situ by the MTT assay.
In vivo model
Female nude mice were purchased from and maintained by the
Biological Research Facility in a pathogen-free environment
at SGUL. Animals were acclimatised for at least 7 days before
each experiment, and were used at the age of 9–13 weeks. All
procedures were conducted in accordance with, and approved,
by the Home Office of the United Kingdom.
Exponentially growing HCT116 cells were harvested, washed
and re-suspended in PBS at a concentration of 1 10
7ml
 1. Only
cells with a viability of 490%, as assessed by trypan blue dye
exclusion analysis, were used. Tumour cell suspension (300ml) was
then injected subcutaneously into the dorsolateral flanks of the
mice and allowed to establish. Upon reaching an approximate size
of 5mm 5mm, CPM (100mgkg
 1), GEM (50mgkg
 1) or OXP
(10mgkg
 1) was administered daily by intra-peritoneal injection.
Drugs were used at clinical achievable doses. Mice were killed
3 days post treatment, and tumour masses were resected and
cells disaggregated before assessing HLA1 expression as described
previously.
Generating immature DCs
Peripheral blood mononuclear cells were isolated from patho-
logically healthy donor whole blood (National Blood Service)
using Histopaque-1077 (Sigma). The mononuclear fraction was
harvested and red blood cell contamination removed by incuba-
tion in hypotonic ammonium chloride. Cells were washed in PBS
and platelet contamination removed by centrifugation at 200g for
10min, re-suspended at a concentration of 3 10
6ml
 1 in basal
RPMI-1640 culture medium and incubated for 2h in a humidified
atmosphere with 5% CO2 in air at 371C to allow monocyte
adhesion. After this time, the medium that contained non-adherent
cells was aspirated from the culture flasks and stored at  801C for
the T-cell proliferation work. Fresh DC-maturing medium (culture
medium containing 50ngml
 1 interleukin-4 (IL4; Peprotech,
London, UK) and 100ngml
 1 granulocyte macrophage-colony
stimulating factor (GMCSF; SGUL Pharmacy) was then added
to the flasks containing the adherent monocytes. Flasks were
returned to the incubator for a further 7 days and fed q.o.d. with
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cells (DC fraction) were harvested and the purity assessed by
CD11c/HLA–DR/CD14 immuno-discrimination by the flow cyto-
meter. All fluorophore-conjugated antibodies were purchased from
BD Biosciences.
Stimulating DCs with tumour-derived supernatant
Immature DCs were reset at 1 10
5 cellsml
 1 in supernatants
derived from A549 or MCF7 tumour cells cultured with CPM, OXP
or GEM, and maintained in a humidified atmosphere with 5% CO2
in air at 371C for 24h. DCs were harvested, washed in wash buffer
and incubated with a combination of phycoerythrin anti-CD80,
allophycocyanin anti-CD83 and fluorescein isothiocyanate anti-
CD86 (BD Biosciences) for 30min at 41C. Cells were washed in
wash buffer before analyses of the percentages and MFIs of cells
expressing activated DC markers.
T-cell proliferation assays
Allogeneic T cells were washed in warm PBS and cultured with
1mM carboxyfluorescein succinimidyl ester (CFSE; Invitrogen,
Paisley, UK) in basal culture medium for 10min at 371C. Dye was
then quenched by washing thrice in ice-cold medium. DCs that had
been pre-stimulated with tumour-derived supernatant were then
admixed with CFSE-loaded T cells at a ratio of 1:10 (affector
DCs:effector T cells), and cultured in a humidified atmosphere
of 5% CO2 at 371C for 4 days. The magnitudes of CFSE-positivity
of the T cells were then assessed by flow cytometry.
RESULTS
Exposure to chemotherapy
Three chemotherapeutic drugs commonly used in the treatment
of solid tumours were investigated in this study and selected on
the basis of their reported associations with immune modulation.
There were dose-dependant reductions in cell viabilities in
cultures with CPM, OXP and GEM (Table 1). Approximate IC25
concentrations were extrapolated on Emax curves and used in the
in vitro experiments. In the murine study, drugs were used at
clinically relevant concentrations as described in the literature.
HLA1 expression is increased by chemotherapy
Human leucocyte antigen class 1 expression in cells was assessed
by flow cytometry using a proprietary antibody directed against
HLA–ABC and presented as MFI relative to the isotype control.
They ranged from 10±0.67 in A549 to 59±3.1 in Caki2, and
divided into those with low expression (A549 and MCF7) and those
with high (Caki2, HCT116 and PC3) (Figure 1). There was little
effect on HLA1 expression of culturing cells with BIC25
concentrations of CPM or OXP. However, culturing with GEM
caused significant increases within HCT116, A549 and MCF7 cells
(MFI cf. untreated controls: 132±30 vs 33±7.8; 0.23±2.3 vs
10±0.67; and 45±11 vs 18±3.7, respectively; Po0.01) (Figure 1).
Our in vivo model showed HLA1 expression in HCT116 growing
subcutaneously in mice was also increased after treatment with
GEM (Po0.001 cf. untreated controls), but remained unchanged
when treated with CPM or OXP (Figure 1). This was seen just after
3 days of intra-peritoneal administration of drugs. No significant
Table 1 IC50 values. Cell lines were cultured with each of the drugs for
three days before the assessment of the concentration required to reduce
cell numbers by 50% by the methylthiazoletetrazolium (MTT) assay
[lM] Cyclophosphamide Oxaliplatin Gemcitabine
A549 41000 (100) 12±8.9 (1) 13±2.8 (1)
Caki2 41000 (300) 33±14 (3) 13±8.6 (1)
HCT116 41000 (100) 27±23 (1) 7.2±4.2 (0.6)
MCF7 41000 (100) 7.6±7.2 (0.6) 2.3±0.45 (0.3)
PC3 41000 (300) 16±12 (3) 4.9±2.4 (0.6)
Values within the parentheses are BIC25 concentrations as determined by Emax-
fitted curves. Values are in mM and represent the mean and s.d. of at least four
separate experiments.
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Figure 1 Chemotherapy increases human leucocyte antigen class 1 (HLA1) expression in tumour cells. Tumour cell lines were cultured with equi-
active BIC25 concentrations of each of the drugs for 3 days before the assessment of HLA1 (HLA–ABC) expression by flow cytometry. Represen-
tative histograms of expressions in MCF7 are shown (inset), where I ¼ isotype control, 0 ¼ control, o ¼ oxaliplatin, c ¼ cyclophosphamide and
g ¼ gemcitabine. Each data column is a representative of the mean and s.d. of at least three separate experiments. In vivo HCT116 data generated from
the mean and s.e.m. of five mice.
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schanges to tumour masses were observed after this short time-
course (data not shown).
HLA1 expression is associated with cytotoxic T-cell
function
We investigated the effect of HLA1 expression on the functional
ability of cytotoxic T cells to induce cellular death by subjecting
those tumour cells with drug-increased HLA1 to the cytotoxic
effects of a modified mixed lymphocyte reaction. Results indicated
reductions in cell number and a concomitant increase in cell death
after exposure to supernatant derived from OXP or GEM as
assessed by the MTT and LDH assays, respectively (Figure 2A).
These effects were most clear with cells cultured in GEM-derived
supernatant, in which the changes in HLA1 expression were most
pronounced. Blockade of HLA1 with an antibody (clone W6/32)
in cells showing the greatest cytotoxic effect (HCT116 and
MCF7) reduced the extent of death. This was achieved at a lower
concentration of 1mgml
 1 in MCF7 cells and at 10mgml
 1 in
HCT116 (Figure 2B), and coincided with the extent of increased
HLA1 expression.
Supernatants from tumours treated with chemotherapy
stimulate DCs
Initial flow cytometric analyses (data not shown) of the effects of
supernatants derived from tumour cells treated with chemotherapy
on peripheral blood mononuclear cells showed no changes in
MFI or percentage of cells in the natural killer (NK), T-cell and
regulatory T-cell (T-reg) subsets. However, there were changes in
the monocyte population, and so we explored more carefully, the
effects of the supernatants on professional APCs from this fraction.
Our plastic adherence method of DC-generation resulted in high
yields (B80% of total event population – based on FSC and SSC
patterns) and the purities of the DCs (CD11cþ, HLA–DRþ and
CD14
low) were 495%. The presence of undifferentiated monocytes
was low with an average CD11cþ and CD14
high signal of 1.5%.
Culturing the DCs with chemotherapy alone resulted in no
significant changes to CD80, CD83 and CD86 expressions as
defined by both percentage of positive cells (percentage of cells)
and MFI (Figure 3C). Although there were significant increases in
these differentiation markers on culturing DCs with supernatant
derived from A549 and MCF7 tumours, there were further
increases in expressions when the supernatant were from tumour
cells treated with chemotherapy (Figure 3A-C).
Supernatant-stimulated DCs enhance the proliferation
of allogeneic T cells
Carboxyfluorescein succinimidyl ester-loaded T cells were
admixed with DCs stimulated with tumour-derived supernatant
and the effect on proliferation was assessed by enumerating T-cell
colony numbers and flow cytometric analyses of CFSE-signals in
T cells. Greatest changes in DC-markers were seen in A549 cells
cultured with chemotherapy and so the ability of these DCs to
stimulate T-cell proliferation was studied. Initial simple morpho-
logical examination of colonies showed significant increases in
their number in cultures with DC pre-treated with supernatants
derived from tumours (Figure 4). Results were recapitulated in
the CFSE-loaded T-cell experiments, which showed increases in
the percentage of proliferating CD3þ/CD4þ and CD3þ/CD8þ
T cells cultured with DCs derived from exposures to basal medium
Gemcitabine – ++
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Figure 2 Human leucocyte antigen class 1 (HLA1) expression is associated with cytotoxic T-cell function. A549, HCT116 and MCF7 cell lines were
cultured with equi-active BIC25 concentrations of each of the drugs for 3 days. Drugs were then removed and the cells were washed before being admixed
with cytotoxic T cells at a ratio of 20:1. (A) Cultures were maintained for a further 24h before the assessment of cell death/viability by the lactate
dehydrogenase (LDH) and methylthiazoletetrazolium (MTT) assays. There were significant increases in cytoxicity (LDH: upper panel) and concomitant
decreases in cell number (MTT: lower panel) in those cultures where gemcitabine was used. (B) Blockade of HLA1 in HCT116 and MCF7 cells by using
antibodies negated the cell death associated with increased HLA1 expression. There was little change to cytotoxicity in cells treated with the isotype control
antibody, which was used at 10mgml
 1. Each data column is a representative of the mean and s.d. of at least three separate experiments.
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s(7.3±1.9% and 2.9±0.059%, respectively), which were not
significantly different to proliferation seen in T cells admixed
with DCs exposed to supernatant derived from untreated A549
tumour (Figure 5A, B). T-cell proliferations were further increased
when the DCs were pre-exposed to chemotherapy, which was
significant when using supernatant from tumours cultured with
GEM (Figure 5C).
DISCUSSION
This study was undertaken as part of our larger remit to investigate
whether immunotherapies could enhance the activities of other
modalities and, thus, improve the outcome and quality of life in
cancer patients. In this study, we specifically investigated the
immunopotentiating effects of CPM, OXP and GEM on a panel of
cancer cell lines. By using in vitro models, we could assess the
effects of these traditional chemotherapeutic agents on immune
cells and tumour cells in isolation. In summary, our results showed
that these cytotoxic drugs had the supplementary effect of
potentially enhancing adaptive immune responses through a dual
effect of increasing DC function that augmented a T-cell response
and partial restoration of immune-visibility of tumour cells to
T cells by an upregulation of HLA1 expression.
Enhancing the body’s natural ability to trigger the immune
system to kill cancer cells underlies the principle of biological
therapies. These can take the form of interferons (IFNs) and
growth factors, as well as a DC-vaccine approach (Dalgleish, 2004;
Copier and Dalgleish, 2006), which are administered as an attempt
to stimulate or restore the ability of the immune system to fight
disease (Weiner et al, 2009). Recently, chemotherapeutic agents
have been added to the list of biological response modifiers. These
drugs are not tumour specific and affect other rapidly proliferating
cells and so consequently, bone marrow-derived haematopoeitic
progenitor cells will also be affected, which reduces blood cell
function. Therefore, chemotherapy should be immunosuppressive;
however, it can have the opposite effect and actually enhance
immune function (Chaudhuri et al, 2009).
The underlying mechanism of immunopotentiation for most
chemotherapeutic drugs is unknown but paradoxically, may be
a consequence of their cytotoxic and immunosuppressive effects.
For example, the cytotoxic alkylating agent CPM can also
selectively inhibit T-regs (Meyer et al, 2009). This effect coupled
with the intrinsic response of immune stem cells to rapidly
mobilise and replace lymphocytes lost to CPM, can induce a quasi-
hypercytokinemic event that ‘boosts’ the pool of functional T cells
(Brode and Cooke, 2008). In addition, CPM may potentiate these
T cells by supporting the production of T-cell-related growth
factors such as type I IFNs (Schiavoni et al, 2000). These immuno-
stimulatory events have been known since the mid-1980s, and
originate from a direct effect of the drugs on immune cells (Berd
et al, 1984; Livingston et al, 1987). However, little is known about
the indirect effects of chemotherapy on immunity. Indeed, their
cytotoxic effect towards tumour cells would generate a rich source
of antigens and cytokines, which could benefit and support
immune responses. For this reason, we explored the concept that
the exhausted culture media from cells treated with chemotherapy
may be immunologically active.
Preliminary experiments showed that supernatants from
tumours treated with any of the drugs had no direct effect on
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Figure 3 Supernatants from tumours treated with chemotherapy stimulate dendritic cells (DCs). DC-derived monocytes were cultured with exhausted
culture media from A549 and MCF7 treated cells. The geometric mean fluorescence intensities (GMFIs) and percentages (percentage of cells) of expressions
of the maturation markers CD80, CD83 and CD86 were assessed after 24h by flow cytometry. Representative density plots with %cells distribution within
each quadrant (A) and histograms highlighting the GMFI within the defined range (B) are shown for DCs exposed to A549-derived media. These media
were from cultures treated with cyclophosphamide (CPM), oxaliplatin (OXP) or gemcitabine (GEM). Tumour-free basal medium (BM) and media from
untreated tumour cells (control) were also included. (C) There were generally increases in the markers (either in terms of GMFI and/or percentage of cells)
upon exposure to supernatants from cyclophosphamide (C), oxaliplatin (O) or gemcitabine (G) compared with untreated tumours (0), which was most
clear in the A549 cohort of samples. Each column is a representative of the mean of at least three separate experiments and s.d. has been omitted for clarity.
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sthe numbers and/or activation states of NKs (CD3 , CD69þ,
CD56þ and CD16þ), T cells (CD3þ, CD25þ and CD69þ) and
T-regs (CD4þ, CD25þ and Foxp3þ). However, significant
changes were seen in the professional APCs (CD3 , CD80þ,
CD83þ and CD86þ) population (data not shown). Consequently,
we explored more carefully, the effects of these supernatants on
monocyte-derived DCs. DCs have an important role in the
development of adaptive immune responses to antigens by
influencing the differentiation of naive T cells into effector T cells
(Steinman, 1991). Treatment of these DCs with supernatants
derived from MCF7-treated tumours had no significant effect of
DC markers. However, treatment with those derived from A549
resulted in a greater extent of maturation and increased expression
of co-stimulatory markers (MFIs and/or percentage of cells), which
indicated immune activation (Dilioglou et al, 2003). Each of the
drugs was used at equi-toxic concentrations and the effect was
drug-specific, with GEM-derived supernatant being most DC-
maturing and CPM the least.
After antigen uptake and processing, mature DCs migrate to
sentinel lymph nodes where they can interact with naive T cells.
Therefore, we next tested the functional ability of these mature
DCs to engage allogeneic T cells by using a modified mixed
lymphocyte reaction, in which DCs pre-exposed to supernatant
were admixed with allogeneic CFSE-loaded T cells (Lyons, 2000).
The A549 tumour cell line was only used in these experiments as
they exhibited greatest change in CD80/83/86 expression, and so
would be most likely to activate T cells. Results showed increased
proliferation of CD3þ/CD4þ and CD3þ/CD8þ cells in cultures
wherein the supernatants were DC-maturing, which were signi-
ficant where maturation was greatest (GEM-derived supernatant).
Increased proliferation was also associated with increased
production of IFN-g (data not shown).
Dendritic cells are specialised APCs that are able to process and
present antigens to T cells, which enables the immune system to
mount an antigen-specific immune response against tumour cells.
They are commonly used as vaccines (Mocellin et al, 2004).
DC-vaccine therapy involves generating immature DCs in vitro by
culturing peripheral blood monocytes with GMCSF and IL4, before
exposing them to cancer-specific antigens and re-administration
into the patient. Maturation is essential for eliciting an immune
response (de Vries et al, 2003) and is commonly induced by
culturing in a cocktail of tumour necrosis factor-a, IL-1b, IL6 and
prostaglandin-E2 (Jonuleit et al, 1997). These cytokines are used to
prepare vaccines for cancer patients; however, our results suggest
that maturation may be achieved by exposing immature DCs to
supernatants derived from tumours without the need for other
growth factors. Also, these supernatants are rich sources of
tumour-derived antigens that can support a cytotoxic T-cell
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Figure 4 Supernatant-stimulated dendritic cells (DCs) increase the number of T-cell colonies. DCs matured with supernatant (CM) derived from A549
treated with cyclophosphamide (CPM), oxaliplatin (OXP) or gemcitabine (GEM) were admixed with allogeneic T cells and the number of colonies present
enumerated on day 4. There were significantly larger numbers of colonies in wells containing DCs pre-exposed to chemotherapy-treated tumour. Typical
pictures of colonies seen in each condition are shown, and each data column. Each data point is a representative of the mean and s.d. of five separate
experiments.
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sresponse. Similarly, the strong possibility that tumours cells
challenged with chemotherapy are producing cytokines that
potentiate DC function is interesting, and forms the basis of an
ongoing parallel study. Although our results stem from allogeneic
experiments, the idea that supernatants derived specifically from
tumours treated with some forms of chemotherapy can enhance
adaptive immune responses is attractive. These data support the
idea of combinations between immune-based and conventional
cancer therapies, and so we are currently investigating these effects
in an autologous system.
A decrease in the expression and/or function of HLA1 has often
been found in tumour cells, which may provide a route through
which adaptive T-cell responses can escape (Cabrera et al, 2003;
Aptsiauri et al, 2007). The deficiency can be caused by loss of
transcription and translation elements (Garrido et al, 1993) or
epigenetic modifications that silence regulatory genes (Tomasi
et al, 2006). Losses can also result from dysregulations of cellular
signalling pathways, which are commonly altered in cancer cells.
Parenthetically, these pro-oncogenic events can, in addition to
promoting tumour growth and survival, reduce immune visibility
(Bianco et al, 2006). HLA1 expression was assessed in our small
group of tumour cell lines and the basal levels varied from
relatively high (Caki2) to low (A549). As cytotoxic T cells are
restricted by HLA1 and kill tumour cells only in the presence of
HLA1, tumours lacking this antigen may be undetected by immune
cells. Consequently, enhancing HLA1 expression could restore
immune visibility in tumour cells. This has been shown possible by
irradiation (Klein et al, 1994), hence we next assessed the effects of
chemotherapy on HLA1 expression on tumours. Results showed
that treatment with BIC25 concentrations of GEM could increase
the expression of HLA1 in tumour cells; some of which exhibited
low basal levels. HLA1 upregulation was recapitulated in vivo in
GEM-treated HCT116 tumour cells grown subcutaneously in nude
mice.
The cytotoxic effect of T cells on tumour lines with increased
HLA1 expression was assessed by a modified mixed lymphocyte
reaction, wherein allogeneic CD3þ sorted cells were admixed with
tumours. The magnitude of cell killing was established by
measuring LDH release from cells and by assessing cell numbers
by the MTT assay. Results showed there was increased cytotoxic
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Figure 5 Supernatant-stimulated DCs increase the proliferation of T cells in vitro. DCs matured with supernatant (CM) derived from A549 treated with
cyclophosphamide (CPM), oxaliplatin (OXP) or gemcitabine (GEM) were admixed with allogeneic T cells loaded with carboxyfluorescein succinimidyl ester
(CFSE). (A, B) Proliferation as indicated by a downward shift of CFSE mean fluorescence intensity was increased after culture with the positive control of
PHA. Both CD4þ and CD8þ subsets were assessed. (C) There was a trend of increased percentage of proliferating T cells cultured with DCs stimulated
with CM, which was significant (Po0.03) in the samples involving GEM. Each data column is a representative of the mean and s.d. of three separate
experiments.
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expression, which was HLA1 specific, as cytotoxicity was reduced
by using a blockade antibody (Fayen et al, 1998). Furthermore,
antagonism was only effective at higher antibody concentrations in
HCT116; a cell line in which HLA1 expression was increased the
most. Technically, there was a general agreement between the
assays, with increases in cytotoxicity associated with decreased cell
numbers. There were some differences, for instance the increased
LDH release in OXP treated MCF7 cells were not recapitulated by a
decrease in MTT signal. The discrepancy between, and limitations
in, the assays have been noted previously (Lobner, 2000; Fotakis
and Timbrell, 2006; Liu and Dalgleish, 2009) and could be because
of the washing steps that are part of the MTT assay, whereas the
LDH assay uses the culture medium directly from the cells.
Nevertheless, the possibility of increasing HLA1 in tumours that
have low expression as a way of enhancing immune responses
is appealing and is highlighted in this study.
Restoration of HLA1 expression can also have the opposite effect
of rendering tumour cells refractory to NK cell mediated lysis.
Specifically, the expression of a subset of HLA1 molecule can disrupt
NK activity, thereby allowing tumour cells to escape innate immune
responses (Storkus et al, 1991). Consequently, a reduction in its
expression may be a more favourable event. Our results also showed
that in addition to increases in HLA1 expression, some drugs used
in the correct tumour type could reduce HLA1 expression (i.e. OXP
in MCF7; Figure 1). This presents the fascinating possibility of
mixing and matching chemotherapies to modify HLA1 expression in
a way to exploit both the adaptive and innate immune responses
(Rees and Mian, 1999). This is currently being investigated.
In summary, early studies have suggested that the induction of
an effective immune response could lead to the elimination of
residual tumour. Subsequent attempts to enhance the immune
response have essentially been on vaccine basis, trying to induce
a specific response against the tumour. Numerous vaccine
approaches have claimed to provide significant clinical benefits,
but very few of these have survived a randomised trial. Much is
known about barriers to effective vaccine therapy and it is
generally assumed that ‘vaccine with something else’ is best. With
our improved understanding that a number of chemotherapeutic
agents have, in addition to their conventional anti-cancer effects,
an element of immune stimulation means that treatment strategies
can be developed to exploit the duality of these drugs. Using
chemotherapy as an adjuvant to immunotherapy could work in a
number of ways. Tumour burden would be reduced through its
direct cytotoxic effect, which would simultaneously generate a
source of cancer-derived antigens in the form of cellular debris.
Furthermore, it could restore immunovisibility by increasing
HLA1 and simultaneously enhance the response of the immune
system to immunotherapies.
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